A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Stomach Neoplasms
Interventions: DRUG: ARX788
Sponsor: Zhejiang Medicine Co., Ltd.
Collaborators: Ambrx, Inc.